These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

772 related items for PubMed ID: 11059779

  • 21. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
    Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G.
    Prostate; 2005 May 01; 63(2):155-68. PubMed ID: 15486991
    [Abstract] [Full Text] [Related]

  • 22. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC.
    Prostate; 2006 Jul 01; 66(10):1070-5. PubMed ID: 16637076
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.
    Jia L, Coetzee GA.
    Cancer Res; 2005 Sep 01; 65(17):8003-8. PubMed ID: 16140973
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A.
    J Mol Endocrinol; 2009 May 01; 42(5):429-35. PubMed ID: 19223455
    [Abstract] [Full Text] [Related]

  • 26. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.
    Wang LG, Ossowski L, Ferrari AC.
    Oncogene; 2004 Jul 01; 23(30):5175-84. PubMed ID: 15156193
    [Abstract] [Full Text] [Related]

  • 27. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.
    Shigemura K, Sung SY, Kubo H, Arnold RS, Fujisawa M, Gotoh A, Zhau HE, Chung LW.
    Prostate; 2007 May 15; 67(7):722-31. PubMed ID: 17342749
    [Abstract] [Full Text] [Related]

  • 28. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B.
    Prostate; 2008 Mar 01; 68(4):453-61. PubMed ID: 18196538
    [Abstract] [Full Text] [Related]

  • 29. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
    Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS.
    Cancer Res; 2006 Nov 01; 66(21):10613-20. PubMed ID: 17079486
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A, Fraizer GC, Piantanelli L, Saunders GF.
    Anticancer Res; 2001 Nov 01; 21(1A):1-10. PubMed ID: 11299720
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is up-regulated by androgens in LNCaP human prostate cancer cells.
    Qi H, Fillion C, Labrie Y, Grenier J, Fournier A, Berger L, El-Alfy M, Labrie C.
    Cancer Res; 2002 Feb 01; 62(3):721-33. PubMed ID: 11830526
    [Abstract] [Full Text] [Related]

  • 34. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
    Mashima T, Okabe S, Seimiya H.
    Mol Pharmacol; 2010 Nov 01; 78(5):846-54. PubMed ID: 20709811
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC, Astapova I, Hollenberg AN, Balk SP.
    Cancer Res; 2007 Sep 01; 67(17):8388-95. PubMed ID: 17804755
    [Abstract] [Full Text] [Related]

  • 37. Synergistic activation of the androgen receptor by bombesin and low-dose androgen.
    Dai J, Shen R, Sumitomo M, Stahl R, Navarro D, Gershengorn MC, Nanus DM.
    Clin Cancer Res; 2002 Jul 01; 8(7):2399-405. PubMed ID: 12114445
    [Abstract] [Full Text] [Related]

  • 38. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
    Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC.
    Cancer Res; 1999 May 01; 59(9):2136-41. PubMed ID: 10232600
    [Abstract] [Full Text] [Related]

  • 39. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
    Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA.
    Mol Cancer Res; 2003 Mar 01; 1(5):385-92. PubMed ID: 12651911
    [Abstract] [Full Text] [Related]

  • 40. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
    Wang LG, Ossowski L, Ferrari AC.
    Cancer Res; 2001 Oct 15; 61(20):7544-51. PubMed ID: 11606392
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.